1. Oh, J. I., Paek, K.-S., Ahn, M.-J., Kim, M.-Y., Hong, C. Y., Kim, I.-C. et al. (1996). In vitro and in vivo evaluation of LB20304, a new fluoronaphthyridinone. Antimicrobial Agents and Chemotherapy40, 1564–8.
2. Comican, M. G. & Jones, R. N. (1997). Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy41,204– 11.
3. Working Party of the British Society for Antimicrobial Chemotherapy. (1991). A guide to sensitivity testing. Journal of Antimicrobial Chemotherapy27, Suppl. D.
4. Andrews, J. M. & Wise, R. (1989). Disc sensitivity testing with ciprofloxacin. Journal of Antimicrobial Chemotherapy23, 156–8.
5. Kelly, L. M., Jacobs, M. R. & Appelbaum, P. C. (1998). Anti-pneumococcal activity of gemifloxacin a new broad-spectrum quinolone, compared with nine compounds by MIC. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-087. p. 254. American Society for Microbiology, Washington, DC.